The a V b 3 / a V b 5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model

Timo L.M. ten Hagen, Ann L.B. Seynhaeve, Gisela aan de Wiel-Ambagtsheer, Ernst A. de Bruijn, Sandra T. van Tiel, Curzio Ruegg, Michael Meyring, Matthias Grell, Simon L. Goodman and Alexander M.M. Eggermont 1 Department of Surgery, Section Surgical Oncology, Laboratory Experimental Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands 2 Department of Experimental Oncology, University of Leuven, Leuven, Belgium 3 Division of Experimental Oncology, Centre Pluridisciplinaire d’Oncologie, University of Lausanne and University Hospital, Lausanne, Switzerland 4 Department of Medicine, Faculty of Sciences, University of Fribourg and Swiss Institute for Experimental Cancer Research, NCCR Molecular Oncology, Epalinges, Switzerland Merck KGaA, Institute of Drug Metabolism and Pharmacokinetics, Grafing, Germany Merck KGaA, Oncology Research and Development, Darmstadt, Germany 7 Institut de Canc erologie Gustave Roussy, Villejuif/Paris, France

[1]  Mohammad Wahid Ansari,et al.  The legal status of in vitro embryos , 2014 .

[2]  M. Hegi,et al.  A safety run‐in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) , 2012, Cancer.

[3]  W. Semmler,et al.  Cilengitide inhibits metastatic bone colonization in a nude rat model. , 2011, Oncology reports.

[4]  Wolfhard Semmler,et al.  Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo study , 2011, International journal of cancer.

[5]  T. Brümmendorf,et al.  Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part , 2011, British Journal of Cancer.

[6]  J. Uhm.  Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma , 2011 .

[7]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[8]  Horst Kessler,et al.  Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.

[9]  Stephen L. Brown,et al.  Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule‐dependency , 2009, International journal of cancer.

[10]  G. Alghisi,et al.  The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells , 2009, PLoS ONE.

[11]  T. Mikkelsen,et al.  Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Alghisi,et al.  Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. , 2006, Endothelium : journal of endothelial cell research.

[14]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[15]  A. Eggermont,et al.  Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. , 2004, Journal of the National Cancer Institute.

[16]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[17]  S. Goodman,et al.  alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. , 2003, Angiogenesis.

[18]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. , 2003, European journal of cancer.

[19]  Thilo Stehle,et al.  Crystal Structure of the Extracellular Segment of Integrin αVβ3 in Complex with an Arg-Gly-Asp Ligand , 2002, Science.

[20]  K. Messmer,et al.  Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo , 2002, British Journal of Cancer.

[21]  G. Denardo,et al.  Combined modality radioimmunotherapy , 2002, Cancer.

[22]  K. Lamborn,et al.  Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. , 2002, Cancer research.

[23]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[24]  A. Eggermont,et al.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion , 2000, British Journal of Cancer.

[25]  A. Eggermont,et al.  TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects , 2000, British Journal of Cancer.

[26]  A. Eggermont,et al.  Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats , 1999, British Journal of Cancer.

[27]  S. Goodman,et al.  N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. , 1999, Journal of medicinal chemistry.

[28]  R. K. Malik.  Regulation of apoptosis by integrin receptors. , 1997, Journal of pediatric hematology/oncology.

[29]  D. Ruiter,et al.  Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. , 1997, International journal of cancer.

[30]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[31]  J. Martínez,et al.  An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. , 1995, Journal of cell science.

[32]  D. Cheresh,et al.  REVIEW: the integrin alpha V beta 3: angiogenesis and apoptosis. , 1995, Cell adhesion and communication.

[33]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[34]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[35]  D. Denhardt,et al.  Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  P. McKeown-Longo,et al.  The alpha v beta 5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. , 1993, The Journal of biological chemistry.

[37]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[38]  D. Cheresh,et al.  Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. , 1992, The Journal of clinical investigation.

[39]  M. Hendrix,et al.  Role of the alpha v beta 3 integrin in human melanoma cell invasion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Goodman,et al.  Multiple cell surface receptors for the short arms of laminin: alpha 1 beta 1 integrin and RGD-dependent proteins mediate cell attachment only to domains III in murine tumor laminin , 1991, The Journal of cell biology.

[41]  D. Cheresh.  Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells. , 1991, Cancer metastasis reviews.

[42]  R. Kramer,et al.  The integrin complex alpha v beta 3 participates in the adhesion of microvascular endothelial cells to fibronectin. , 1991, Experimental cell research.

[43]  Jeffrey W. Smith,et al.  The vitronectin receptor alpha v beta 3 binds fibronectin and acts in concert with alpha 5 beta 1 in promoting cellular attachment and spreading on fibronectin , 1990, The Journal of cell biology.

[44]  U. Tjaden,et al.  Chromatographic analysis of anticancer drugs. , 1990, Journal of chromatography.

[45]  D. Cheresh,et al.  Purification and functional characterization of integrin alpha v beta 5. An adhesion receptor for vitronectin. , 1990, The Journal of biological chemistry.

[46]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[47]  J W Smith,et al.  Integrin (alpha v beta 3)-ligand interaction. Identification of a heterodimeric RGD binding site on the vitronectin receptor. , 1990, The Journal of biological chemistry.

[48]  D. Cheresh.  Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.